StarPRJ_Detail_EN

Flu-based COVID-19 Vaccine - Gold Medal with Congratulations of Jury

Summary: It is a flu-based nasal spray COVID-19 vaccine that could generate immunity against both flu and COVID-19.

Technology Benefits: Easy to use; Highly safe; provide both mucosal and systemic immune response

Detailed Technology Description: It is live attenuated with the deletion of the key virulent element and immune antagonist, NS1, from the viral genome and is potentially more immunogenic than wild type influenza virus. It uses flu vector to express a specific antigen to induce immunity targeting the critical element of the Receptor Binding Domain (RBD) of SARS-CoVs. Such strategy may avoid potential antibody dependent enhancement (ADE) as observed in the experimental vaccine for SARS-CoV.
It can be produced in chicken embryonated eggs and MDCK cells which are proven production systems for influenza vaccines. Its features are highly safe and is used as nasal spray to induce both local mucosal immune response and systemic immune response by simulating the natural infection pathway of respiratory viruses.

Application No.: US Provisional Application No. 62/972,616;

US Provisional Application No.63/037,645;

PCT/CN2021/075527